Legal News, In Brief: Copaxone, AngioMax, Cipro, Botox, OxyContin
Executive Summary
Teva Wins Ruling On Copaxone Patents
You may also be interested in...
Copaxone Patent Suit: Is Teva Really Sure It Wants To Win The Case?
The bench trial in Teva Pharmaceutical USA Inc.'s Copaxone (glatiramer) patent infringement suit against Mylan Pharmaceuticals Inc. and Sandoz Inc. concluded on Sept. 21 and the parties now await a decision by the judge. If Teva is successful, it may end up asking itself what a victory in this patent battle would cost in the broader war on biosimilars.
Copaxone Patent Suit: Is Teva Really Sure It Wants To Win The Case?
The bench trial in Teva Pharmaceutical USA Inc.'s Copaxone (glatiramer) patent infringement suit against Mylan Pharmaceuticals Inc. and Sandoz Inc. concluded on Sept. 21 and the parties now await a decision by the judge. If Teva is successful, it may end up asking itself what a victory in this patent battle would cost in the broader war on biosimilars.
The Medicines Company Is Almost Ready To Celebrate Angiomax Patent Term Extension
Studies of additional indications for the product may resume as the Patent and Trademark Office assesses the potential length of the extension, which could protect the product until mid-2015.